中(zhong)國證券網訊(記者 史(shi)文超) 第一(yi)(yi)醫(yi)(yi)藥公(gong)(gong)(gong)(gong)告,公(gong)(gong)(gong)(gong)司(si)(si)接到實控(kong)人(ren)百(bai)聯(lian)(lian)(lian)集團(tuan)(tuan)通知,百(bai)聯(lian)(lian)(lian)集團(tuan)(tuan)與公(gong)(gong)(gong)(gong)司(si)(si)第一(yi)(yi)大股(gu)東上海新路達商業(集團(tuan)(tuan))有(you)限(xian)(xian)(xian)(xian)公(gong)(gong)(gong)(gong)司(si)(si)以及公(gong)(gong)(gong)(gong)司(si)(si)股(gu)東華聯(lian)(lian)(lian)(集團(tuan)(tuan))有(you)限(xian)(xian)(xian)(xian)公(gong)(gong)(gong)(gong)司(si)(si)于(yu)3月(yue)27日分別簽(qian)訂(ding)了(le)《百(bai)聯(lian)(lian)(lian)集團(tuan)(tuan)有(you)限(xian)(xian)(xian)(xian)公(gong)(gong)(gong)(gong)司(si)(si)與上海新路達商業(集團(tuan)(tuan))有(you)限(xian)(xian)(xian)(xian)公(gong)(gong)(gong)(gong)司(si)(si)關于(yu)上海第一(yi)(yi)醫(yi)(yi)藥股(gu)份(fen)有(you)限(xian)(xian)(xian)(xian)公(gong)(gong)(gong)(gong)司(si)(si)之股(gu)份(fen)無(wu)(wu)償劃(hua)轉(zhuan)協(xie)議(yi)(yi)》、《百(bai)聯(lian)(lian)(lian)集團(tuan)(tuan)有(you)限(xian)(xian)(xian)(xian)公(gong)(gong)(gong)(gong)司(si)(si)與華聯(lian)(lian)(lian)(集團(tuan)(tuan))有(you)限(xian)(xian)(xian)(xian)公(gong)(gong)(gong)(gong)司(si)(si)關于(yu)上海第一(yi)(yi)醫(yi)(yi)藥股(gu)份(fen)有(you)限(xian)(xian)(xian)(xian)公(gong)(gong)(gong)(gong)司(si)(si)之股(gu)份(fen)無(wu)(wu)償劃(hua)轉(zhuan)協(xie)議(yi)(yi)》,擬將(jiang)新路達所(suo)持公(gong)(gong)(gong)(gong)司(si)(si)52,185,126股(gu)股(gu)份(fen)、華聯(lian)(lian)(lian)集團(tuan)(tuan)所(suo)持公(gong)(gong)(gong)(gong)司(si)(si)1,331,583股(gu)股(gu)份(fen)分別無(wu)(wu)償劃(hua)轉(zhuan)至百(bai)聯(lian)(lian)(lian)集團(tuan)(tuan)直接持有(you)。
本(ben)次(ci)劃轉事宜完(wan)成后,百(bai)聯(lian)(lian)(lian)集團將直接持(chi)有公(gong)(gong)(gong)司(si)(si)股(gu)份98,021,194股(gu),占(zhan)公(gong)(gong)(gong)司(si)(si)股(gu)份總數的43.94%,新路(lu)達和(he)華聯(lian)(lian)(lian)集團將不(bu)再持(chi)有公(gong)(gong)(gong)司(si)(si)股(gu)份。公(gong)(gong)(gong)司(si)(si)控股(gu)股(gu)東將由新路(lu)達變更為百(bai)聯(lian)(lian)(lian)集團,公(gong)(gong)(gong)司(si)(si)實(shi)際控制人(ren)未(wei)發生變化,仍為百(bai)聯(lian)(lian)(lian)集團和(he)上海市國資委。